Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-17
2007-04-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S200000, C562S567000, C560S252000
Reexamination Certificate
active
10813954
ABSTRACT:
The invention relates to the compound of the formula 1and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
REFERENCES:
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221897 (2001-04-01), Frick et al.
patent: 6245744 (2001-06-01), Frick et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6624185 (2003-09-01), Glombik et al.
patent: 6884812 (2005-04-01), Glombik et al.
patent: 2004/0082561 (2004-04-01), Jaehne et al.
patent: 2005/0239766 (2005-10-01), Starke et al.
patent: 2005/0267038 (2005-12-01), Glombik et al.
patent: 0462884 (1993-06-01), None
patent: 0 656 354 (1997-06-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 99/15525 (1999-04-01), None
patent: WO 99/46262 (1999-09-01), None
patent: WO 00/34331 (2000-06-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/71549 (2000-11-01), None
patent: WO 00/78312 (2000-12-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/90094 (2001-11-01), None
patent: WO 02/44150 (2002-06-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 03/015769 (2003-02-01), None
Asakawa A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastic Emptying in Mice, Hormone and Metabolic Research, (2001) vol. 33, No. 9, pp. 554-558.
Barf Tjeerd et al., Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11 Beta-Hydroxysteroid Dehydrogenase Type 1, American Chemical Society, (2002), vol. 45, No. 18, pp. 3813-3815.
Ishihara Kazuaki et al., 3,4,5-Trifluorobenzeneboronic Acid as an Extremely Active Amidation Catalyst, J. Org. Chem., (1996), vol. 61, pp. 4196-4197.
Klausner Yakir S. et al., Coupling Reagents in Peptide Synthesis.
Kunishima Munetaka et al., 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium Chloride: An Efficient Condensing Agent Leading to the Formation of Amides and Esters, Tetrahedron, (1999), vol. 55, pp. 13159-13170.
Larock, R.C., Interconversion of Nitriles, Carboxylic Acids and Derivatives, Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, New York, Weinheim; 1999; pp. 1929-1930.
Lee Daniel W. et al., Leptin Agonists as a Potential Approach to the Treatment of Obesity, Drugs of the Future, (2001), vol. 26, No. 9, pp. 873-881.
Okada H. et al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull., (1994), vol. 42, No. 1, pp. 57-61.
Salvador Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opinion Pharmacotherapy, (2001), vol. 2, No. 10, pp. 1615-1622.
Speicher A. et al., O-(1-Benzotriazolyl)-N,N,N,N,-tetramethyluroniumhexafluorophosphat (HBTU) und O-(7-Aza-1-benzotriazolyl)-N,N,N,N -tetramethyluroniumhexafluorophosphat (HATU) -zwei moderne Kupplungsreagenzien zur Peptidsynthese, J. prakt. Chem., (1998), vol. 340, pp. 581-583.
Zunfit H. J. F. et al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Therapy, (2001), vol. 18, No. 5, pp. 230-236.
Flohr Stefanie
Frick Wendelin
Galia Eric
Glombik Heiner
Heuer Hubert
Berch Mark L.
Kurys Barbara E.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Diphenylazetidinone with improved physiological properties,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylazetidinone with improved physiological properties,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylazetidinone with improved physiological properties,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780017